Company Overview
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
Recent News
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
Amarantus Provides Corporate Update
MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology
Stock Overview
Symbol
AMBS
Exchange
OTCPink
Shares OS
68,272,000
Market Cap
$1.37M
Last Price
$0.02
52-Week Range
$0.018 - $0.2085
Fiscal Year End
December 31
Last Trade Time
12/12/2018 09:56 AM EST
Investor Relations
American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com